FDA Rejects Proposed Chronic Kidney Disease Indication for Vytorin
In SHARP, VYTORIN 10/20 mg lowered LDL cholesterol in patients with moderate to severe chronic kidney disease (CKD), and major vascular events were reduced in the treatment group compared to placebo. The trial therefore demonstrated that treatment with ...
FDA fails to approve cholesterol drug for kidney diseaseReuters
FDA Turns Down Expanded Use of Merck's Vytorin and ZetiaBusinessWeek
Vytorin US label updated with SHARP resultsTheHeart.Org
MedPage Today -Cardiology Today
all 40 news articles »